Unique ID issued by UMIN | UMIN000038037 |
---|---|
Receipt number | R000043364 |
Scientific Title | The attenuating effect of HBF2019-03 on postprandial serum triglyceride level in healthy human subjects -A placebo controlled, randomized, double blind, cross-over study- |
Date of disclosure of the study information | 2019/09/21 |
Last modified on | 2020/03/19 10:45:24 |
The attenuating effect of HBF2019-03 on postprandial serum triglyceride level in healthy human subjects -A placebo controlled, randomized, double blind, cross-over study-
The attenuating effect of HBF2019-03 on postprandial serum triglyceride level.
The attenuating effect of HBF2019-03 on postprandial serum triglyceride level in healthy human subjects -A placebo controlled, randomized, double blind, cross-over study-
The attenuating effect of HBF2019-03 on postprandial serum triglyceride level.
Japan |
N/A (healthy adults)
Adult |
Others
NO
To evaluate the efficacy of HBF2019-03 on the suppression of the elevation of postprandial serum triglyceride.
Safety,Efficacy
Time course of serum triglyceride level and AUC (area under the curve) (0-6hrs)
*Secondary outcomes
Time course of serum RLP-cholesterol level and AUC (area under the curve) (0-6hrs)
*Safety
Doctor's questions
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
YES
2
Treatment
Food |
Placebo food (a single time intake) -> 1-week washout -> Test food, containing HBF2019-03 (a single time intake)
Test food, containing HBF2019-03 (a single time intake) -> 1-week washout -> Placebo food (a single time intake)
20 | years-old | <= |
65 | years-old | > |
Male and Female
[1] Healthy males and females aged 20-64 years old when informed consent.
[2] Fasting serum triglyceride level is between 120 and 200 mg/dL.
[3] Who don't large amount of alcohol habitually.
[4] Who are judged not suffering from a disease by the investigator.
[5] Individuals giving written informed consent.
[1] Who use medical products affecting lipid metabolism.
[2] Who can't stop using supplements which affecting lipid metabolism during the study period.
[3] Who can't abstinent from alcohol from two days before each examination.
[4] Who are allergic to placebo food and/or test food and/or the ingredient of high-fat meal.
[5] Who have a history of serious kidney damage, hepatopathy, heart disease, respiratory disease, endocrine disease, or any other metabolic disease(s) or who is under medical treatment.
[6] Who have chronic disease and is under medication.
[7] Who have digestive organ disease or surgical history affecting digestion and absorption of foods.
[8] Who are judged inappropriate for the study by the investigator in the screening.
[9] Who are diagnosed as severe anemia in screening and not suitable for frequent collection of blood.
[10] Who had an onset diarrhea within a week from the date of screening, and/or who are prone to diarrhea on a daily basis.
[11] Who with significantly different fasting serum triglycerides levels of each test day.
[12] Who have little change in serum triglyceride level after intake high-fat meal, or who continue to rise 6 hours after the meal, or who are judged abnormal changes in serum triglyceride level by the investigator in the screening.
[13] Who donated blood over 200mL in the past a month or over 400mL in the past 3 months from the date of informed consent.
[14] Who are diagnosed as familial hyperlipidemia.
[15] Who are drug addict and/or alcohol addict.
[16] Who with irregular life rhythms such as shift workers or works late at night.
[17] Who are participating in other studies that using food(s), pharmaceutical(s), and cosmetic(s) now, or who have participated or are willing to participate in other studies within a month from the date of informed consent.
[18] Who are or are possibly pregnant, or who are lactating, during the study period.
[19] Who are judged inappropriate for the study by the investigator.
90
1st name | Yoshitaka |
Middle name | |
Last name | Iwama |
Nihonbashi Cardiology Clinic
Director
103-0001
Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
03-5641-4133
yiwama@well-sleep.jp
1st name | Yoshika |
Middle name | |
Last name | Komori |
KSO Corporation
Sales department
105-0023
Shibaura-omodaka Bldg. 7F, 1-9-7, Shibaura, Minato-ku, Tokyo
03-3452-7733
yoshi@kso.co.jp
KSO Corporation
Hayashibara CO., LTD.
Profit organization
Ethical Committee of Nihonbashi Cardiology Clinic
Kyodo Bldg. #201, 13 - 4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo
03-5641-4133
niho-jimucho@well-sleep.jp
NO
医療法人財団健康睡眠会 日本橋循環器科クリニック(東京都)
/Nihonbashi Cardiology Clinic(Tokyo)
2019 | Year | 09 | Month | 21 | Day |
Unpublished
90
Completed
2019 | Year | 09 | Month | 10 | Day |
2019 | Year | 09 | Month | 10 | Day |
2019 | Year | 09 | Month | 21 | Day |
2019 | Year | 11 | Month | 10 | Day |
2019 | Year | 09 | Month | 18 | Day |
2020 | Year | 03 | Month | 19 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043364
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |